NZ591615A - Benzoquinoline inhibitors of vesicular monoamine transporter 2 - Google Patents

Benzoquinoline inhibitors of vesicular monoamine transporter 2

Info

Publication number
NZ591615A
NZ591615A NZ591615A NZ59161509A NZ591615A NZ 591615 A NZ591615 A NZ 591615A NZ 591615 A NZ591615 A NZ 591615A NZ 59161509 A NZ59161509 A NZ 59161509A NZ 591615 A NZ591615 A NZ 591615A
Authority
NZ
New Zealand
Prior art keywords
compound
recited
iponz
received
deuterium
Prior art date
Application number
NZ591615A
Other languages
English (en)
Inventor
Thomas G Gant
Manoucherhr Shahbaz
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of NZ591615A publication Critical patent/NZ591615A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ591615A 2008-09-18 2009-09-18 Benzoquinoline inhibitors of vesicular monoamine transporter 2 NZ591615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9789608P 2008-09-18 2008-09-18
PCT/US2009/057480 WO2010044981A2 (en) 2008-09-18 2009-09-18 Benzoquinoline inhibitors of vesicular monoamine transporter 2

Publications (1)

Publication Number Publication Date
NZ591615A true NZ591615A (en) 2012-07-27

Family

ID=42107127

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591615A NZ591615A (en) 2008-09-18 2009-09-18 Benzoquinoline inhibitors of vesicular monoamine transporter 2

Country Status (20)

Country Link
US (16) US8524733B2 (cg-RX-API-DMAC7.html)
EP (4) EP3061760B1 (cg-RX-API-DMAC7.html)
JP (3) JP5616345B2 (cg-RX-API-DMAC7.html)
CN (2) CN102186848B (cg-RX-API-DMAC7.html)
AU (1) AU2009303758B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0913457B8 (cg-RX-API-DMAC7.html)
CA (2) CA2972242A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120060T1 (cg-RX-API-DMAC7.html)
DK (2) DK2326643T3 (cg-RX-API-DMAC7.html)
ES (4) ES2425623T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180239T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038158T2 (cg-RX-API-DMAC7.html)
LT (1) LT3061760T (cg-RX-API-DMAC7.html)
NO (1) NO3061760T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ591615A (cg-RX-API-DMAC7.html)
PL (1) PL3061760T3 (cg-RX-API-DMAC7.html)
PT (1) PT3061760T (cg-RX-API-DMAC7.html)
SI (1) SI3061760T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800067T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010044981A2 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3061760T3 (cg-RX-API-DMAC7.html) * 2008-09-18 2018-04-07
PT2499139E (pt) * 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
PL3222266T3 (pl) 2010-08-27 2018-10-31 Sienna Biopharmaceuticals, Inc. Kompozycje i sposoby do termomodulacji celowanej
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
NZ705372A (en) * 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
KR20200106984A (ko) 2012-10-11 2020-09-15 나노콤포식스, 인크. 은 나노플레이트 조성물 및 방법
HK1219095A1 (zh) * 2013-01-31 2017-03-24 Auspex Pharmaceuticals, Inc. Vmat2的benzoquinolone抑制剂
WO2015048370A1 (en) * 2013-09-27 2015-04-02 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
EP3071565A4 (en) * 2013-11-22 2017-08-02 Auspex Pharmaceuticals, Inc. Methods of treating abnormal muscular activity
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2930744A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP3099299A4 (en) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (ru) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
JP6635945B2 (ja) 2014-05-06 2020-01-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 多動性運動障害を処置するためのｖｍａｔ２インヒビター
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CN114796209A (zh) 2015-03-06 2022-07-29 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
WO2016154017A1 (en) * 2015-03-20 2016-09-29 Sienna Biopharmaceuticals, Inc. Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles
JP7109360B2 (ja) 2015-10-30 2022-07-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10479787B2 (en) 2016-04-22 2019-11-19 Lupin Limited Process for preparation of tetrabenazine and deutetrabenazine
WO2017221169A1 (en) 2016-06-24 2017-12-28 Lupin Limited Premixes of deutetrabenazine
CN107936008B (zh) * 2016-10-13 2022-06-14 泰州华元医药科技有限公司 氘代化合物及其医药用途
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
EA201991782A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
JP7608050B2 (ja) * 2017-03-15 2025-01-06 オースペックス ファーマシューティカルズ インコーポレイテッド デューテトラベナジンの類似体、その調製及び使用
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019074492A1 (en) 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
US10786495B2 (en) * 2017-10-10 2020-09-29 The Regents Of The University Of California Vesicular monoamine transporter 2 inhibitors for treating stuttering
WO2019130252A2 (en) * 2017-12-29 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing deutetrabenazine
CN111655243A (zh) 2018-01-29 2020-09-11 乔纳森·萨克纳-伯恩斯坦 在人类神经系统疾病中调节多巴胺的方法
WO2019150387A1 (en) * 2018-02-01 2019-08-08 Alaparthi Lakshmi Prasad A novel process for preparation of deutetrabenazine
WO2019166962A1 (en) 2018-03-01 2019-09-06 Mylan Laboratories Ltd Deutetrabenazine polymorphs and methods for their preparation
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US10632107B2 (en) 2018-05-14 2020-04-28 Apotex Inc. Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
CN108794337A (zh) * 2018-07-10 2018-11-13 上海华堇生物技术有限责任公司 一种3,4-二羟基-β-硝基苯乙烯的新制备方法
IL320987A (en) 2018-08-15 2025-07-01 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
MA53904A (fr) 2018-10-18 2021-08-25 Oncopeptides Ab Composés contenant du deutérium
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
PE20230852A1 (es) 2020-06-10 2023-05-29 Auspex Pharmaceuticals Inc Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas
KR20230067636A (ko) 2020-09-17 2023-05-16 오스펙스 파마슈티칼스, 인코포레이티드 듀테트라베나진을 포함하는 다중미립자 제형
WO2022081532A1 (en) 2020-10-12 2022-04-21 Auspex Pharmaceuticals, Inc. Gastro retentive dosage forms comprising deutetrabenazine
AU2022241988A1 (en) 2021-03-22 2023-10-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
MX2023014827A (es) 2021-06-30 2024-01-15 Neurocrine Biosciences Inc Valbenazina para usarse en el tratamiento complementario de la esquizofrenia.
JP2024535862A (ja) 2021-09-17 2024-10-02 オースペックス ファーマシューティカルズ インコーポレイテッド デューテトラベナジンを含む多粒子剤形
WO2023133201A1 (en) 2022-01-05 2023-07-13 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
IL315181A (en) 2022-03-07 2024-10-01 Neurocrine Biosciences Inc Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
IL317235A (en) 2022-06-08 2025-01-01 Auspex Pharmaceuticals Inc Osmotic dosage forms comprising ditetrabenzene and methods of using the same
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025259267A1 (en) 2024-06-11 2025-12-18 Vector Vitale Ip Llc Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) 1958-04-15 Quinolizine derivatives
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
AT238201B (de) * 1961-03-28 1965-01-25 Mta Verfahren zur Herstellung von Chinolizinderivaten
US4316897A (en) * 1980-09-10 1982-02-23 Hoffmann-La Roche Inc. Method of lowering serum prolactin
AU707748B2 (en) * 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
WO2007130365A2 (en) 2006-05-02 2007-11-15 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
PT2081929E (pt) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
EP2078026B1 (en) 2006-11-21 2012-01-04 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
US20100204258A1 (en) * 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
WO2009003226A1 (en) 2007-06-29 2009-01-08 Clarencew Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
WO2009124357A1 (en) 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
NO3061760T3 (cg-RX-API-DMAC7.html) 2008-09-18 2018-04-07
US20100113496A1 (en) * 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
AU2011218805A1 (en) 2010-02-24 2012-08-30 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2

Also Published As

Publication number Publication date
CY1120060T1 (el) 2018-12-12
US20160375005A1 (en) 2016-12-29
EP2610254A1 (en) 2013-07-03
US20250326747A1 (en) 2025-10-23
US20220267317A1 (en) 2022-08-25
US20130296360A1 (en) 2013-11-07
JP5616345B2 (ja) 2014-10-29
EP3345905A1 (en) 2018-07-11
JP2015007124A (ja) 2015-01-15
PL3061760T3 (pl) 2018-07-31
US20140206713A1 (en) 2014-07-24
LT3061760T (lt) 2018-02-26
US8524733B2 (en) 2013-09-03
AU2009303758B8 (en) 2015-02-19
SMT201800067T1 (it) 2018-03-08
AU2009303758A1 (en) 2010-04-22
JP5970037B2 (ja) 2016-08-17
CN102186848B (zh) 2014-11-12
ES2652289T3 (es) 2018-02-01
CA2736409C (en) 2017-07-11
BRPI0913457B8 (pt) 2021-08-31
US20100130480A1 (en) 2010-05-27
US20160367548A1 (en) 2016-12-22
CN104311552A (zh) 2015-01-28
DK3061760T3 (en) 2018-02-05
WO2010044981A3 (en) 2010-06-17
JP2016172782A (ja) 2016-09-29
CA2736409A1 (en) 2010-04-22
HK1222853A1 (en) 2017-07-14
DK2326643T3 (da) 2013-08-05
US20150328207A1 (en) 2015-11-19
EP2326643A2 (en) 2011-06-01
US20170166562A1 (en) 2017-06-15
HUE038158T2 (hu) 2018-09-28
US20140206712A1 (en) 2014-07-24
US20160220558A1 (en) 2016-08-04
EP2610254B1 (en) 2015-11-25
NO3061760T3 (cg-RX-API-DMAC7.html) 2018-04-07
BRPI0913457B1 (pt) 2021-07-20
PT3061760T (pt) 2018-01-04
US20190375746A1 (en) 2019-12-12
AU2009303758B2 (en) 2014-10-23
JP6138322B2 (ja) 2017-05-31
EP3061760A1 (en) 2016-08-31
US20150080427A1 (en) 2015-03-19
AU2009303758A8 (en) 2015-02-19
CN102186848A (zh) 2011-09-14
HRP20180239T1 (hr) 2018-05-18
ES2896678T3 (es) 2022-02-25
HK1186728A1 (en) 2014-03-21
SI3061760T1 (en) 2018-04-30
EP3061760B1 (en) 2017-11-08
US20160158220A1 (en) 2016-06-09
HK1257880A1 (en) 2019-11-01
ES2425623T3 (es) 2013-10-16
EP3345905B1 (en) 2021-09-01
JP2012503010A (ja) 2012-02-02
US20140350044A1 (en) 2014-11-27
BRPI0913457A2 (pt) 2020-06-09
EP2326643B1 (en) 2013-05-29
EP2326643A4 (en) 2012-03-21
CA2972242A1 (en) 2010-04-22
US20200347048A1 (en) 2020-11-05
ES2563820T3 (es) 2016-03-16
WO2010044981A2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
AU2009303758B2 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2011261551B2 (en) Benzoquinolone inhibitors of VMAT2
WO2015048370A1 (en) Benzoquinolone inhibitors of vmat2
HK1257880B (en) Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
HK1222853B (en) Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
HK1186728B (en) Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 SEP 2016 BY CPA GLOBAL

Effective date: 20130801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2017 BY DENNEMEYER + CO

Effective date: 20160819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2018 BY DENNEMEYER + CO

Effective date: 20170822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2019 BY DENNEMEYER + CO

Effective date: 20180821

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2020 BY DENNEMEYER + CO

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2021 BY DENNEMEYER + CO.

Effective date: 20200907

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2022 BY DENNEMEYER + CO

Effective date: 20210911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220905

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2024 BY ANAQUA SERVICES

Effective date: 20230823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2025 BY ANAQUA SERVICES

Effective date: 20240820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2026 BY ANAQUA SERVICES

Effective date: 20250820